Paper · 39250424
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
Collinson F and 31 others. Health Technol Assess, 2024. Cited by 0 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Papers, record 39250424. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39250424
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
- PubMed
- Publication types
- Journal Article, Multicenter Study, Randomized Controlled Trial, Clinical Trial, Phase II, Clinical Trial, Phase III, Research Support, Non-U.S. Gov't, Equivalence Trial
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Kidney Neoplasms | Major topic |
| Carcinoma, Renal Cell | Major topic |
| Protein Kinase Inhibitors | Major topic |
| Quality-Adjusted Life Years | Major topic |
| Humans | |
| Male | |
| Female | |
| Middle Aged | |
| Aged | |
| United Kingdom | |
| Withholding Treatment | |
| Sunitinib | |
| Technology Assessment, Biomedical | |
| Adult | |
| Antineoplastic Agents | |
| Tyrosine Kinase Inhibitors |
Source PubMed
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References107
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,779,529 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. | N Engl J Med | 2019 | https://conductscience.org/library/papers/30779529 | PubMed |
| 2 | 21,969,501 | Alternative end points to evaluate a therapeutic strategy in advanced colorectal cancer: evaluation of progression-free survival, duration of disease control, and time to failure of strategy--an Aide et Recherche en Cancerologie Digestive Group Study. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21969501 | PubMed |
| 3 | 20,028,918 | Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. | AJR Am J Roentgenol | 2010 | https://conductscience.org/library/papers/20028918 | PubMed |
| 4 | 21,813,743 | Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. | Radiology | 2011 | https://conductscience.org/library/papers/21813743 | PubMed |
| 5 | 23,227,058 | Understanding noninferiority trials. | Korean J Pediatr | 2012 | https://conductscience.org/library/papers/23227058 | PubMed |
| 6 | 26,482,279 | Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26482279 | PubMed |
| 7 | 31,225,907 | Adjuvant therapy in renal cell carcinoma. | Cancer | 2019 | https://conductscience.org/library/papers/31225907 | PubMed |
| 8 | 19,097,774 | New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). | Eur J Cancer | 2009 | https://conductscience.org/library/papers/19097774 | PubMed |
| 9 | 26,406,150 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406150 | PubMed |
| 10 | 26,406,148 | Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26406148 | PubMed |
1 to 10 of 107
See all 107 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 0 citations.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39250424
GET https://conductscience.org/api/papers/v1/39250424/authors?page=2